Abstract:
Compounds having the formula or a pharmaceutically acceptable salt thereof wherein Ris (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L—, and (i) heterocyclic-L—; Ris selected from (a) (b) —C(O)NH—CH(R)—C(O)OR, (c) (d) —C(O)NH—CH(R)—C(O)NHSOR(e) —C(O)NH—CH(R)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R)—C(O)NRR; Ris heterocyclic, aryl, substituted or unsubstituted cycloalkyl; Ris hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; Lis absent or is selected from (a) —L—N(R)—L—, (b) —L—O—L—, (c) —L—S(O)—L— (d) —L-L—C(W)—N(R)—L—, (e) —L-L—S(O)—N(R)—L—, (f) —L—N(R)—C(W)—L-L—, (g) —L—N(R)—S(O)—L—L—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.